168 results
Page 2 of 9
8-K
EX-10.3
itufitpbsrx
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
8komye06 bbj
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
rohujc49
22 May 23
Business combination disclosure
7:01am
8-K
jjrvdb9xbl wsc8ikeyu
22 May 23
Other Events
6:59am
424B3
pllq5f7f
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
EX-5.1
hgdzl7f11ft7
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
s0iurcs
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
iit 3iy6itan7
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
l11yr9df
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
usqylkd
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
417lf6d 2z0ys
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am
8-K
th2r7me4f8ac9s
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
1ffq7rzkk h45qc
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
aexfwiw8071k 7tb4s6l
28 Apr 22
Prospectus supplement for primary offering
8:09am